# Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

> **NCT06771544** · PHASE2 · RECRUITING · sponsor: **University of California, Irvine** · enrollment: 14 (estimated)

## Conditions studied

- Melanoma
- Melanoma Stage III
- Melanoma (Skin)
- Melanoma Stage IV

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06771544
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771544, "Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06771544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*